Mass Spectrometry for Neurobiomarker Discovery: The Relevance of Post-Translational Modifications
Open Access
Abstract
Neurodegenerative diseases are incurable, heterogeneous, and age-dependent disorders that challenge modern medicine. A deeper understanding of the pathogenesis underlying neurodegenerative diseases is necessary to solve the unmet need for new diagnostic biomarkers and disease-modifying therapy and reduce these diseases’ burden. Specifically, post-translational modifications (PTMs) play a significant role in neurodegeneration. Due to its proximity to the brain parenchyma, cerebrospinal fluid (CSF) has long been used as an indirect way to measure changes in the brain. Mass spectrometry (MS) analysis in neurodegenerative diseases focusing on PTMs and in the context of biomarker discovery has improved and opened venues for analyzing more complex matrices such as brain tissue and blood. Notably, phosphorylated tau protein, truncated α-synuclein, APP and TDP-43, and many other modifications were extensively characterized by MS. Great potential is underlying specific pathological PTM-signatures for clinical application. This review focuses on PTM-modified proteins involved in neurodegenerative diseases and highlights the most important and recent breakthroughs in MS-based biomarker discovery.Keywords
Funding Information
- Fondation pour la Recherche sur Alzheimer (Mass-Spec-Tau)
This publication has 149 references indexed in Scilit:
- Systematic and Quantitative Assessment of the Ubiquitin-Modified ProteomeMolecular Cell, 2011
- Expanding the proteome: disordered and alternatively folded proteinsQuarterly Reviews of Biophysics, 2011
- Site-specific characterization of threonine, serine, and tyrosine glycosylations of amyloid precursor protein/amyloid β-peptides in human cerebrospinal fluidProceedings of the National Academy of Sciences, 2011
- Acetylation of Tau Inhibits Its Degradation and Contributes to TauopathyNeuron, 2010
- Global analysis of lysine ubiquitination by ubiquitin remnant immunoaffinity profilingNature Biotechnology, 2010
- O-GlcNAc cycling: Implications for neurodegenerative disordersThe International Journal of Biochemistry & Cell Biology, 2009
- Modification‐specific proteomics: Strategies for characterization of post‐translational modifications using enrichment techniquesProteomics, 2009
- Decoding protein modifications using top-down mass spectrometryNature Methods, 2007
- A proteomics approach to understanding protein ubiquitinationNature Biotechnology, 2003
- α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with Lewy bodiesProceedings of the National Academy of Sciences, 1998